Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review

References

• Khan MA, Hashim MJ, Mustafa H, et al. Global epidemiology of ischemic heart disease: results from the global burden of disease study. Cureus. 2020;12(7):e9349.
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The global burden of cardiovascular diseases and risk: a compass for future health. J Am Coll Cardiol. 2022;80(25):2361–2371.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Joseph P, Rangarajan S, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2020;395(10226):795–808.
   PubMed Web of Science ®Google Scholar
• Whelton SP, McEvoy JW, Shaw L, et al. Association of normal systolic blood pressure level with cardiovascular disease in the absence of risk factors. JAMA Cardiol. 2020;5(9):1011–1018.
   PubMed Web of Science ®Google Scholar
• Chen C, Li X, Su Y, You Z, Wan R, Hong K. Adherence with cardiovascular medications and the outcomes in patients with coronary arterial disease: “Real‐world” evidence. Clin Cardiol. 2022;45(12):1220–1228.
   PubMed Web of Science ®Google Scholar
• Jeemon P, Severin T, Amodeo C, et al. World heart federation roadmap for hypertension - a 2021 update. Glob Heart. 2021;16(1):63.
   PubMed Web of Science ®Google Scholar
• Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125(9):882–887.e1.
   PubMed Web of Science ®Google Scholar
• Unger T, Borghi C, Charchar F, et al. 2020 international society of hypertension global hypertension practice guidelines. Hypertension. 2020;75(6):1334–1357.
   PubMed Web of Science ®Google Scholar
• World Heart Federation. The polypill could avoid millions of premature deaths, heart attacks and strokes every year, say leading cardiology experts; 2021. Available from: https://world-heart-federation.org/news/the-polypill-could-avoid-millions-of-premature-deaths-heart-attacks-and-strokes-every-year-say-leading-cardiology-experts. Accessed August 22, 2023.
   Google Scholar
• Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326(7404):1419.
   PubMed Web of Science ®Google Scholar
• Sosa-Liprandi A, Sosa-Liprandi MI, Alexanderson E, et al. Clinical impact of the polypill for cardiovascular prevention in latin america: a consensus statement of the inter-American society of cardiology. Glob Heart. 2019;14(1):3–16 e1.
   PubMed Web of Science ®Google Scholar
• Abushouk AI, Sayed A, Munir M, et al. Fixed-dose combination (polypill) for cardiovascular disease prevention: a meta-analysis. Am J Prev Med. 2022;63(3):440–449.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
   PubMed Web of Science ®Google Scholar
• Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340(mar23 1):c869.
   PubMedGoogle Scholar
• Von Elm E, Altman DG, Egger M. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:7626.
   Google Scholar
• Yusuf S, Joseph P, Dans A, et al. Polypill with or without Aspirin in Persons without Cardiovascular Disease. N Engl J Med. 2021;384(3):216–228.
   PubMed Web of Science ®Google Scholar
• Thom S, Poulter N, Field J, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA. 2013;310(9):918–929.
   PubMed Web of Science ®Google Scholar
• Patel A, Cass A, Peiris D, et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol. 2015;22(7):920–930.
   PubMed Web of Science ®Google Scholar
• Selak V, Elley CR, Bullen C, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ. 2014;348:g3318.
   PubMed Web of Science ®Google Scholar
• Lafeber M, Grobbee DE, Schrover IM, et al. Comparison of a morning polypill, evening polypill and individual pills on LDL-cholesterol, ambulatory blood pressure and adherence in high-risk patients; a randomized crossover trial. Int J Cardiol. 2015;181:193–199.
   PubMed Web of Science ®Google Scholar
• Soliman EZ, Mendis S, Dissanayake WP, et al. A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. Trials. 2011;12(1):5675.
   Google Scholar
• Castellano JM, Sanz G, Penalvo JL, et al. A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol. 2014;64(20):2071–2082.
   PubMed Web of Science ®Google Scholar
• Cosin-Sales J, Murcia-Zaragoza JM, Pereyra-Rico HO, la Guia-Galipienso F, Hermans K, Rubio G. Evaluating patients’ satisfaction and preferences with a secondary prevention cardiovascular polypill: the Aurora Study. J Comp Eff Res. 2021;10(13):975–985.
   PubMed Web of Science ®Google Scholar
• Roshandel G, Khoshnia M, Poustchi H, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet. 2019;394(10199):672–683.
   PubMed Web of Science ®Google Scholar
• Ros-Castello V, Natera-Villalba E, Gomez-Lopez A, et al. Use of the cardiovascular polypill in secondary prevention of cerebrovascular disease: a real-life tertiary hospital cohort study of 104 patients. Cerebrovasc Dis Extra. 2020;10(3):166–173.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Juanatey JR, Cordero A, Castellano JM, et al. The CNIC-Polypill reduces recurrent major cardiovascular events in real-life secondary prevention patients in Spain: the NEPTUNO study. Int J Cardiol. 2022;361:116–123.
   PubMed Web of Science ®Google Scholar
• Castellano JM, Pocock SJ, Bhatt DL, et al. Polypill strategy in secondary cardiovascular prevention. N Engl J Med. 2022;387(11):967–977.
   PubMed Web of Science ®Google Scholar
• Mariani J, Rosende A, De Abreu M, et al. Multicap to improve adherence after acute coronary syndromes: results of a randomized controlled clinical trial. Ther Adv Cardiovasc Dis. 2020;14:175394472091207.
   Google Scholar
• Attaei MW, Khatib R, McKee M, et al. Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet Public Health. 2017;2(9):e411–e9.
   PubMed Web of Science ®Google Scholar
• Legido-Quigley H, Camacho Lopez PA, Balabanova D, et al. Patients’ Knowledge, Attitudes, Behaviour and Health Care Experiences on the Prevention, Detection, Management and Control of Hypertension in Colombia: a Qualitative Study. PLoS One. 2015;10(4):e0122112.
   PubMed Web of Science ®Google Scholar
• Rao S, Jamal Siddiqi T, Khan MS, et al. Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: a systematic review and meta-analysis of randomized controlled trials. Prog Cardiovasc Dis. 2022;73:48–55.
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326(7404):1427.
   PubMed Web of Science ®Google Scholar
• Indian Polycap S, Yusuf S, Pais P, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a Phase II, double-blind, randomised trial. Lancet. 2009;373(9672):1341–1351.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Pais P, Sigamani A, et al. Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators. Circ Cardiovasc Qual Outcomes. 2012;5(4):463–471.
   PubMed Web of Science ®Google Scholar
• Joseph P, Roshandel G, Gao P, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet. 2021;398(10306):1133–1146.
   PubMed Web of Science ®Google Scholar